N/A Completed N=200 Randomized Quadruple-blind Diagnostic

Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF

Infertility

Source: ClinicalTrials.gov NCT02739269 ↗

Enrolled (actual)

200

Serious AEs

0.0%

Results posted

Feb 2019

Primary outcomePrimary: Percentage of Subjects Having Desired Ovarian Response — 49; 54 Participants — p=0.479

Summary

This is a prospective randomized trial to compare the use of AFC and serum AMH as the basis for gonadotrophin dosing in in-vitro fertilization treatment. The hypothesis is that the use of serum AMH as the criterion for determination of gonadotrophin dosing in IVF treatment results in more optimal ovarian response than AFC.

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Subjects Having Desired Ovarian Response	49; 54	0.479
SECONDARY Percentage of Subjects Requiring Step-up or Step-down of Gonadotrophin Dose Upon First Ultrasound Tracking	44; 36	0.002 sig

Eligibility Criteria

Inclusion Criteria

Subjects undergoing the first IVF cycle during the study period.

Exclusion Criteria

Body mass index >=30 kg/m2
Subjects in repeated IVF cycles
Subjects undergoing IVF treatment using donor oocytes
Subjects undergoing pre-implantation genetic diagnosis

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02739269). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.